Home › Studies › PRJNA1033532
PRJNA1033532 SRP469293

Ex vivo entacapone/loxapine effects on gut microbiome (Vienna)

Evaluating the impact of pharmaceuticals on the human gut microbiome Raw sequence reads

9 faecal samples from healthy adults in Vienna, Austria, used in an ex vivo intervention study testing how entacapone and loxapine succinate affect gut microbial composition and function. machine-written summary

9 samples · 9 runs · AT · Age unknown · 2024 · 14.71 Gbp / sample

Sources
✓Sequence archive 68○Abstract / description○Full text○Supplementary tables✓External resources 27–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive68 sample values (collection date, country, latitude, location locality, location region, longitude, medication, medication detail)
○ Abstract / descriptionread; no usable statement
○ Full textread; no usable statement or table · PMC11602724
○ Supplementary tablesfiles read; no table could be matched to the samples
✓ External resources27 sample values (antibiotic exposure, health condition, health condition detail) · from BugSigDB
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

design single_arm_before_after

Samples at a glance
1 sampling locations · 1 country
Age
adult9
Condition
healthy_control9
Country
AT9
Body site
primary9
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)all projects, 1–3 Gbp: 124,983 samples (22 %)all projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 2 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 6 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)this project, 30–100 Gbp: 1 samplesall projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 14.71 Gbp per sample0130Gbp
Community composition
Phocaeicola 6.9%Blautia_A 6.7%Roseburia 6.1%Escherichia 5.9%Faecalibacterium 5.8%Prevotella 5.1%Bifidobacterium 4.7%Bacteroides 4.7%Streptococcus 4.1%Ruminococcoides 3.3%Fusicatenibacter 2.4%Collinsella 2.4%not assigned to a genus 4.3%other genera 37.8%

Genera, mean relative abundance over 8 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category9 100%
country9 100%9
health_condition9 100%9
subject_id6 67%6
antibiotic_exposure9 100%9
collection_date9 100%9
detailed_location9 100%
health_condition_detail9 100%9
latitude9 100%9
location_locality9 100%9
location_region9 100%9
longitude9 100%9
timepoint_label6 67%6
medication1 11%1
medication_detail1 11%1
Papers (2)
  • The Parkinson's drug entacapone disrupts gut microbiome homeostasis via iron sequestration. 2023 PMID 38014294 own_data
  • The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration. 2024 PMID 39572788 PMC11602724 own_data
Details
Archive description

Drugs initially designed to specifically target human cells often can affect microbes as well. As a result of poor gastrointestinal absorption and/or biliary secretion, many of these drugs reach the large intestine where they encounter - and potentially interact with - hundreds to thousands of different microbial species that play important roles in various aspects of human physiology. Indeed, several cohort studies have reported significant associations between the use of medication and shifts in gut microbial composition and function. However, much less is known about the mechanisms by which drugs target the microbiome and how drugs affect microbial function. In this study we combined quantitative microbiome profiling and long-read metagenomics, stable isotope probing and single-cell chemical imaging to investigate the impact of two nervous system-targeted drugs on the gut microbiome.Ex vivosupplementation of physiologically relevant concentrations of entacapone or loxapine succinate to faecal samples significantly impacted the abundance of up to one third of the microbial species present. We further demonstrate that entacapone impacts the microbiome due to its ability to complex and deplete available iron, and that microbial growth can be rescued by replenishing levels of microbiota-accessible iron. Collectively, our study unveils the impact of two under-investigated drugs on whole microbiomes and further identifies metal sequestration as a mechanism of drug-induced microbiome disturbance. Sequencing was performed at the Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna under the project IDs JMF-2103-29 and JMF-2208-05.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.75. Assay shotgun_dna.

  • host run.host_tax_id · “9606”
  • body site study.description · “faecal samples”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN38167974antibiotic_exposurenoR20.60external.bugsigdb sourceAntibiotics exclusion: 3 months
SAMN38167974collection_date2021R10.90biosample.attribute:collection_date2021
SAMN38167974countryATR10.90sample.attr.geo_loc_nameAustria: Vienna
SAMN38167974health_conditionhealthy_controlR20.60external.bugsigdb sourcegiven to the six healthy adult individuals
SAMN38167974health_condition_detailResponse to drug (ex vivo incubation)R20.60external.bugsigdb sourceCondition: Response to drug (ex vivo incubation)
SAMN38167974latitude48.2000R10.90biosample.attribute:lat_lon48.20 N 16.37 E
SAMN38167974location_localityViennaR10.85biosample.attribute:geo_loc_nameAustria: Vienna
SAMN38167974location_regionViennaR10.85biosample.attribute:geo_loc_nameAustria: Vienna
SAMN38167974longitude16.3700R10.90biosample.attribute:lat_lon48.20 N 16.37 E
SAMN38167981medicationother_medicationR10.75biosample.attribute:treatmentDMSO+Entacapone
SAMN38167981medication_detailDMSO+EntacaponeR10.75biosample.attribute:treatmentDMSO+Entacapone
SAMN38167974subject_idvolunteer1R10.70sample.name_rule:TITLEfecalsample_volunteer1
SAMN38167974timepoint_label1R10.70sample.name_rule:aliasJMF-2110-04-0001 FS_V1
Sequencing

9 runs over 9 samples · mean 20.97 Gbp per run (median 14.71 Gbp, total 188.70 Gbp; 9 runs with a base count) · layout PAIRED 8, SINGLE 1 · platform ILLUMINA 8, OXFORD_NANOPORE 1 · models Illumina NovaSeq 6000 (8), PromethION (1) · 89% of runs with a Sandpiper profile · first public 2024-09-24

Authors (23)

Centre for Microbiology and Environmental Systems Science, Department of Microbiology and Ecosystem Science, University of Vienna, Vienna, Austria. first · Department of Electrical & Computer Engineering, Boston University, Boston, Massachusetts, USA. · Department of Chemistry, Boston University, Boston, Massachusetts, USA. · Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria. · Boettcher T · Pereira FC first · Ge X · Kristensen JM · Kirkegaard RH · Maritsch K · Szamosvári D · Imminger S · Seki D · Shazzad JB · Zhu Y · Decorte M · Hausmann B · Berry D · Wasmund K · Schintlmeister A · Böttcher T · Cheng JX · Wagner M last

Downloads

PRJNA1033532.csv.gz (1.2 KB) · parquet (71.3 KB) — all 9 samples, every field with route and confidence · PRJNA1033532_determinations.csv.gz (1.8 KB) — 95 evidence rows

Samples (9 · every field this project has values for · hover a cell for its source)
Loading the sample table…